India Markets close in 4 hrs 35 mins

USFDA completes inspection of Lupin's Nagpur plant

Faizan Javed
1 / 1

Lupin to launch nearly 30 products in US market this fiscal

The Mumbai-based company currently has 162 abbreviated new drug applications (ANDAs) pending approval with the US Food and Drug Administration (USFDA).

Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin "announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations".

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 percent higher at Rs 767.50 on BSE.